Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 10/20 | 0.40 |
| ▸ | TP53 | P04637 | 9/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 4/20 | 0.37 |
| ▸ | RAB9A | P51151 | 4/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.37 |
| ▸ | RELA | Q04206 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 5/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2586411 | 1.00 | SMN1; SMN2 (0.40) | SMN1; SMN2TP53THRBNPC1RAB9A | |
| SCHEMBL15914064 | 0.83 | SMN1; SMN2 (0.39) | SMN1; SMN2TP53THRBNPC1RAB9A | |
| SCHEMBL14853198 | 0.83 | SMN1; SMN2 (0.39) | SMN1; SMN2TP53THRBNPC1RAB9A | |
| SCHEMBL2579226 | 0.81 | MAPT (0.39) | SMN1; SMN2TP53THRBNPC1RAB9A | |
| SCHEMBL16104464 | 0.71 | ADORA1 (0.34) | SMN1; SMN2TP53L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL2576712 | 0.66 | CCR5 (0.40) | TP53 | |
| SCHEMBL2584012 | 0.66 | EPHX2 (0.42) | — | |
| SCHEMBL2576715 | 0.66 | CCR5 (0.40) | TP53 | |
| SCHEMBL2587909 | 0.66 | ALDH1A1 (0.34) | SMN1; SMN2TP53NPC1RAB9AMEN1 | |
| SCHEMBL2587912 | 0.66 | ALDH1A1 (0.34) | SMN1; SMN2TP53NPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2763997-B1 | CYCLOHEXYL-4H,6H-5-OXA-2,3,10B-TRIAZA-BENZO[E]AZULENES AS V1A ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2017-08-02 | — | — | EP | disclosed |
| US-9346824-B2 | Cyclohexyl-4H,6H-5-oxa-2,3,10b-triaza-benzo[e]azulenes as V1a antagonists | HOFFMAN-LA ROCHE, INC. (US) | 2016-05-24 | — | — | US | disclosed |
| EP-2569319-B1 | HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES | HOFFMANN LA ROCHE (CH) | 2014-09-24 | — | — | EP | disclosed |
| EP-2763997-A1 | CYCLOHEXYL-4H,6H-5-OXA-2,3,10B-TRIAZA-BENZO[E]AZULENES AS V1A ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-08-13 | — | — | EP | disclosed |
| US-20140221350-A1 | Cyclohexyl-4H,6H-5-oxa-2,3,10b-triaza-benzo[e]azulenes as V1a antagonists | HOFFMANN-LA ROCHE INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8513238-B2 | Heteroaryl-cyclohexyl-tetraazabenzo[E]azulenes | HOFFMANN-LA ROCHE INC. (US) | 2013-08-20 | — | — | US | disclosed |
| WO-2013050334-A1 | CYCLOHEXYL-4H,6H-5-OXA-2,3,10B-TRIAZA-BENZO[E]AZULENES AS V1A ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-04-11 | — | — | WO | disclosed |
| EP-2569319-A1 | HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-03-20 | — | — | EP | disclosed |
| WO-2011141396-A1 | HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-11-17 | — | — | WO | disclosed |
| US-20110275801-A1 | HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES | HOFFMANN-LA ROCHE, INC. | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221350-A1 | Cyclohexyl-4H,6H-5-oxa-2,3,10b-triaza-benzo[e]azulenes as V1a antagonists | AVPR1A, AVPR1B, OXTR | SMN1; SMN2 2648/4885TP53 3456/4885THRB 166/4885 |
| US-20110275801-A1 | HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES | AVPR1A, AVPR1B, OXTR | SMN1; SMN2 3953/4885TP53 3546/4885THRB 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.